Cargando…

Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event

The spectrum of TKI-related adverse events (AEs) is variable. Pleural effusion (PE) is a frequent AE attributable to dasatinib treatment, while it is only rarely associated with nilotinib. The pathogenetic mechanism leading to PE during nilotinib therapy is still unknown and its management has not y...

Descripción completa

Detalles Bibliográficos
Autores principales: Pasquale, Raffaella, Bucelli, Cristina, Bellani, Valentina, Zappa, Manuela, Iurlo, Alessandra, Cattaneo, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513037/
https://www.ncbi.nlm.nih.gov/pubmed/36176390
http://dx.doi.org/10.3389/fonc.2022.1012268
_version_ 1784797965637910528
author Pasquale, Raffaella
Bucelli, Cristina
Bellani, Valentina
Zappa, Manuela
Iurlo, Alessandra
Cattaneo, Daniele
author_facet Pasquale, Raffaella
Bucelli, Cristina
Bellani, Valentina
Zappa, Manuela
Iurlo, Alessandra
Cattaneo, Daniele
author_sort Pasquale, Raffaella
collection PubMed
description The spectrum of TKI-related adverse events (AEs) is variable. Pleural effusion (PE) is a frequent AE attributable to dasatinib treatment, while it is only rarely associated with nilotinib. The pathogenetic mechanism leading to PE during nilotinib therapy is still unknown and its management has not yet been defined. To the best of our knowledge, only a limited number of similar case reports have already been reported in the literature so far. Here, we describe the case of a 41-year-old CML patient who developed PE during first-line nilotinib, successfully treated with steroids and nilotinib permanent discontinuation. We highlight the differences among our patient and the others, proposing therapeutic strategies to solve this rare but still possible AE, of which physicians should be aware.
format Online
Article
Text
id pubmed-9513037
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95130372022-09-28 Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event Pasquale, Raffaella Bucelli, Cristina Bellani, Valentina Zappa, Manuela Iurlo, Alessandra Cattaneo, Daniele Front Oncol Oncology The spectrum of TKI-related adverse events (AEs) is variable. Pleural effusion (PE) is a frequent AE attributable to dasatinib treatment, while it is only rarely associated with nilotinib. The pathogenetic mechanism leading to PE during nilotinib therapy is still unknown and its management has not yet been defined. To the best of our knowledge, only a limited number of similar case reports have already been reported in the literature so far. Here, we describe the case of a 41-year-old CML patient who developed PE during first-line nilotinib, successfully treated with steroids and nilotinib permanent discontinuation. We highlight the differences among our patient and the others, proposing therapeutic strategies to solve this rare but still possible AE, of which physicians should be aware. Frontiers Media S.A. 2022-09-13 /pmc/articles/PMC9513037/ /pubmed/36176390 http://dx.doi.org/10.3389/fonc.2022.1012268 Text en Copyright © 2022 Pasquale, Bucelli, Bellani, Zappa, Iurlo and Cattaneo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Pasquale, Raffaella
Bucelli, Cristina
Bellani, Valentina
Zappa, Manuela
Iurlo, Alessandra
Cattaneo, Daniele
Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event
title Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event
title_full Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event
title_fullStr Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event
title_full_unstemmed Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event
title_short Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event
title_sort case report: pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: not only a dasatinib-related adverse event
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513037/
https://www.ncbi.nlm.nih.gov/pubmed/36176390
http://dx.doi.org/10.3389/fonc.2022.1012268
work_keys_str_mv AT pasqualeraffaella casereportpleuraleffusionduringtyrosinekinaseinhibitortreatmentinchronicmyeloidleukemianotonlyadasatinibrelatedadverseevent
AT bucellicristina casereportpleuraleffusionduringtyrosinekinaseinhibitortreatmentinchronicmyeloidleukemianotonlyadasatinibrelatedadverseevent
AT bellanivalentina casereportpleuraleffusionduringtyrosinekinaseinhibitortreatmentinchronicmyeloidleukemianotonlyadasatinibrelatedadverseevent
AT zappamanuela casereportpleuraleffusionduringtyrosinekinaseinhibitortreatmentinchronicmyeloidleukemianotonlyadasatinibrelatedadverseevent
AT iurloalessandra casereportpleuraleffusionduringtyrosinekinaseinhibitortreatmentinchronicmyeloidleukemianotonlyadasatinibrelatedadverseevent
AT cattaneodaniele casereportpleuraleffusionduringtyrosinekinaseinhibitortreatmentinchronicmyeloidleukemianotonlyadasatinibrelatedadverseevent